Zhejiang Taimei Med Tech Co (2576) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Zhejiang Taimei Med Tech Co HK$2.14, price HK$4.68, upside -54.3%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Zhejiang Taimei Med Tech Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
24‑month range HK$3.10 – HK$9.20 · fair‑value band HK$1.41 – HK$2.67 · the HK$4.68 price screens above the HK$2.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Zhejiang Taimei Med Tech Co in your weekly email
Every Wednesday you see whether Zhejiang Taimei Med Tech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally.
Show more
Zhejiang Taimei Medical Technology Co., Ltd. provides digital solutions for life sciences research, development, and commercialization in Mainland China and internationally. The company offers Wiz.AI, an AI platform for clinical trials; TrialOS pharmaceutical R&D collaboration platform; PharmaOS, a pharmaceutical digital marketing platform; and the enterprise-medical academic interaction platform. It also provides pharmaceutical R&D solutions comprising eCollect, eBalance, eCooperate, eArchives, eImage medical imaging evaluation system, eSMS site management system, Paylite financial management system, and eCollege training management system; TrialPartner digital SMO services, IRC independent review center solutions, and eSAE clinical trial safety information management system; eSitePro clinical trial management platform, eTrialPro research ward management system, GCP-X intelligent clinical trial platform, IIT-EDC research data collection system, eScreening subject information management system, eMonitoring intelligent remote monitoring system, and IDS investigational drug services; and IDCT intelligent decentralized clinical trial. In addition, the company offers eSafety pharmacovigilance compliance management system; eSAE clinical trial safety information management system; ONECEM omni-channel marketing platform, such as ONECEM-SFE sales operation system, ONECEM-SCRM intelligent marketing system, and ONECEM-event+engagement system; and ONEInsight marketing data platform, including boundless corporate medical interaction platform. Further, it provides research and development support; technical, clinical operation, data management, statistical analysis, and management services; independent image evaluation services; and pharmaceutical marketing and institution digitalization solutions. The company was formerly known as Jiaxing Taimei Medical Technology Co., Ltd. Zhejiang Taimei Medical Technology Co., Ltd.was founded in 2013 and is headquartered in Jiaxing, China.
Stock analysis
Zhejiang Taimei Med Tech Co (2576) currently trades at HK$4.68, while our model-based Fair Value estimate is HK$2.14, 54.3% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Scenario range: HK$1.41 (bear) to HK$2.67 (bull), the price of HK$4.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Zhejiang Taimei Med Tech Co reported revenue of 499M CNY in FY2025 versus 466M CNY in FY2021, a compound +1.7%/yr. Reported net income was −41.7M CNY in FY2025.
Key figures
Market cap HK$3.8B (≈ $481M) · P/S ratio 7.37 · EPS (TTM) HK$−0.0400 · Net margin −8.4% · Return on equity −4.2% · Return on assets (EBIT) −19.9% · Operating margin −8.8% · Revenue (TTM) 513M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −54%, 2576 screens richer than that median.
Fair Value models
Bear HK$1.41Fair Value HK$2.14Bull HK$2.67
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−108.5% (2021) → −12.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Zhejiang Taimei Med Tech Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−54.3% · Below median
Profitability
Return on assets−2.3% · Below median
Net margin (TTM)−8.4% · Below median
Operating margin (TTM)−8.8% · Below median
Growth and dividend
Revenue growth−3.6% · Bottom 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang Taimei Med Tech Co Fair Value". https://www.fairvalue-calculator.com/stock/2576
Frequently asked questions
Is Zhejiang Taimei Med Tech Co (2576) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$2.14 versus a price of HK$4.68, about −54% upside (overvalued).
What is the fair value of 2576?
Our model-based fair value for Zhejiang Taimei Med Tech Co is HK$2.14 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$4.68.
What is the quality score of 2576?
Zhejiang Taimei Med Tech Co has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Taimei Med Tech Co (2576)?
Our model-based price target is the fair value of HK$2.14 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$1.41, optimistic scenario HK$2.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Taimei Med Tech Co stock forecast for 2026?
Our models put fair value at HK$2.14, about −54% upside versus a price of HK$4.68 (overvalued). Cautious scenario HK$1.41, optimistic scenario HK$2.67. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Taimei Med Tech Co (2576)?
Zhejiang Taimei Med Tech Co reported trailing-twelve-month revenue of about 513M CNY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Zhejiang Taimei Med Tech Co (2576)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Taimei Med Tech Co it is HK$2.14 per share (as of Sep 27, 2026), against a price of HK$4.68. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang Taimei Med Tech Co stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2576 trades above its calculated fair value: price HK$4.68, fair value HK$2.14, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2576?
No. The price is what the market pays today (HK$4.68); the fair value is what the company's own numbers justify (HK$2.14). For Zhejiang Taimei Med Tech Co the two are HK$2.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Taimei Med Tech Co worth?
The market values Zhejiang Taimei Med Tech Co at about HK$3.8B (market capitalisation, as of Sep 27, 2026). Per share that is HK$4.68; our models calculate a fair value of HK$2.14 per share.
What do the bullish and bearish scenarios say about 2576?
Our models span a range for Zhejiang Taimei Med Tech Co: cautious scenario HK$1.41, base HK$2.14, optimistic HK$2.67 per share (as of Sep 27, 2026, price HK$4.68). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhejiang Taimei Med Tech Co (2576)?
Balance-sheet figures for Zhejiang Taimei Med Tech Co (as of Sep 27, 2026): return on equity −4.2%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 2576 from its 52-week high?
Zhejiang Taimei Med Tech Co trades at HK$4.68, about 38% below its 52-week high of HK$7.50 and 25% above the low of HK$3.73 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.14 is for.
Which stocks are comparable to Zhejiang Taimei Med Tech Co?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Taimei Med Tech Co stock attractive at the current price?
The data as of Sep 27, 2026: price HK$4.68, calculated fair value HK$2.14 (−54%), Quality Score 56/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2576 calculated?
We run Zhejiang Taimei Med Tech Co through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.14, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Zhejiang Taimei Med Tech Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Taimei Med Tech Co (2576)?
The closing price on Sep 30, 2026 was HK$4.68. Our model-based fair value is HK$2.14, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Taimei Med Tech Co right now?
The price sits above even our optimistic bull case (HK$2.67). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$1.41 to HK$2.67) leaves room in how you read the outcome.
Key figures of Zhejiang Taimei Med Tech Co
How large is the market capitalisation of Zhejiang Taimei Med Tech Co (2576)?
The market capitalisation of Zhejiang Taimei Med Tech Co is HK$3.8B (≈ $481M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Taimei Med Tech Co (2576)?
The price-to-sales ratio of Zhejiang Taimei Med Tech Co is 7.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Taimei Med Tech Co (2576)?
Earnings per share at Zhejiang Taimei Med Tech Co are HK$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zhejiang Taimei Med Tech Co (2576)?
The net margin of Zhejiang Taimei Med Tech Co is −8.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Taimei Med Tech Co (2576)?
The return on equity (ROE) of Zhejiang Taimei Med Tech Co is −4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Taimei Med Tech Co (2576)?
On an EBIT basis the return on assets of Zhejiang Taimei Med Tech Co is −19.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Taimei Med Tech Co (2576)?
The operating margin of Zhejiang Taimei Med Tech Co is −8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Taimei Med Tech Co (2576)?
Revenue at Zhejiang Taimei Med Tech Co is growing −3.6% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Zhejiang Taimei Med Tech Co (2576) generate?
The free cash flow of Zhejiang Taimei Med Tech Co is −43.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhejiang Taimei Med Tech Co (2576) hold?
Zhejiang Taimei Med Tech Co holds more cash than debt, 564M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Zhejiang Taimei Med Tech Co in the live analysis
One click puts Zhejiang Taimei Med Tech Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
